We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. The PATHFNDR-2 trial enrolled adults with acromegaly who ...

Please provide your email address to receive an email when new articles are posted on . Most participants achieved IGF-1 control and reduced acromegaly symptoms at 1 year with CAM2029. Improvements in ...

Crinetics Pharma's lead asset, Paltusotine, shows promising Phase 3 results for acromegaly, with a PDUFA date set for September 25, 2024. Paltusotine, an oral SST2 agonist, offers advantages over ...

Crinetics Pharmaceuticals' oral med paltusotine regulated levels of a hormone associated with the pituitary gland disorder acromegaly in a phase 3 test, setting up a regulatory submission for the ...